The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

Plasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that
cause the majority of cases of human malaria, have developed resistance to nearly all …

Background Chloroquine, a previous highly efficacious, easy to use and affordable anti-
malarial agent was withdrawn from malaria endemic regions due to high levels of …

The global spread of sulfadoxine (Sdx, S) and pyrimethamine (Pyr, P) resistance is attributed
to increasing number of mutations in DHPS and DHFR enzymes encoded by malaria …

Since 2000, the world has made significant progress in reducing malaria morbidity and
mortality, and several countries in Africa, South America and South‐East Asia are working …

Background Until recently, due to widespread prevalence of molecular markers associated
with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) resistance in east and southern …

Introduction: Plasmodium falciparum, the deadly agent of malaria, is notorious for its
capacity to develop drug resistance. Treatment failures of artemisinin therapy regimens …

Abstract Background In 2005, the Democratic Republic of the Congo (DRC) switched to
artesunate/amodiaquine as the first-line antimalarial in response to increasing sulfadoxine …

Background Despite scale-up of seasonal malaria chemoprevention (SMC) with sulfadoxine-
pyrimethamine and amodiaquine (SP-AQ) in children 3–59 months of age in Burkina Faso …

Antimalarial drug resistance has threatened global malaria control since chloroquine (CQ)-
resistant Plasmodium falciparum emerged in Asia in the 1950s. Understanding the impacts …